Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904721 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
A Phase 2 study of Alopecia and Alopecia, Androgenetic, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 244
- Enrollment target
- 1
- Study location
NCT01904721 is a Phase 2 study of Alopecia and Alopecia, Androgenetic that has completed, run by Allergan. The registered enrollment target is 244 participants, above the 106-participant average among 13 other Alopecia trials with a reported enrollment target (130% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01904721, a Phase 2 study of Alopecia and Alopecia, Androgenetic, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 244 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
Conditions Studied
Interventions
- DRUG Bimatoprost Solution 1
- DRUG Bimatoprost Solution 2
- DRUG Bimatoprost Vehicle
Study Locations (1)
Minnesota
- - Fridley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01904721
The ClinicalTrials.gov registry entry for NCT01904721 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 106-participant average among 13 other Alopecia trials with a reported enrollment target (130% higher). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alopecia appearing as the primary indexed condition, and to 3 interventions - of which Bimatoprost Solution 1 is the first listed.
NCT01904721 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01904721 about?
NCT01904721 is a clinical study titled "A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)". This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
What is the current status of trial NCT01904721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2013-08. Estimated completion is 2015-01.
What conditions does trial NCT01904721 study?
This clinical trial studies the following conditions: Alopecia, Alopecia, Androgenetic, Baldness.
What interventions are being tested in trial NCT01904721?
The interventions under investigation include: Bimatoprost Solution 1 (DRUG), Bimatoprost Solution 2 (DRUG), Bimatoprost Vehicle (DRUG).
Who is sponsoring clinical trial NCT01904721?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01904721 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors
ACTIVE NOT RECRUITING · Phase 2
-
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
RECRUITING · NA
-
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
RECRUITING · NA
-
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
RECRUITING · NA
-
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
RECRUITING · NA
-
Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.